<DOC>
	<DOCNO>NCT00825734</DOCNO>
	<brief_summary>In study , patient metastatic HER2-negative breast cancer receive treatment ixabepilone sorafenib disease progression unacceptable toxicity occur . The Phase I portion study determine maximum tolerated dos ( MTDs ) sorafenib ixabepilone may use combination first- second-line treatment MBC . The MTDs identify Phase I portion study use Phase II portion evaluate efficacy safety combination sorafenib ixabepilone patient receive least one prior chemotherapy treatment either adjuvant neoadjuvant set follow one prior MBC chemotherapy MBC patient receive prior adjuvant neoadjuvant breast cancer chemotherapy . This one initial trial investigate use treatment combination MBC . This trial conduct leadership Sarah Cannon Research Institute ( SCRI ) Oncology Research Consortium , community-based , multi-center , clinical trial organization .</brief_summary>
	<brief_title>Phase I/II Trial Sorafenib Plus Ixabepilone HER2-Negative Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>1 . Age ≥ 18 year . 2 . Histologically cytologically confirm breast cancer diagnosis metastatic disease . Patients without pathologic cytologic confirmation metastatic disease unequivocal evidence metastasis . 3 . Measurable disease , per RECIST criterion ( Therasse et al . 2000 ) . Measurable disease previously irradiate unless progression document . Measurable disease define : least one lesion accurately measure least one dimension [ long diameter record ] &gt; 20 mm conventional technique , &gt; 10 mm spiral compute tomography ( CT ) scan . Disease must measurable , i.e. , boneonly disease evaluableonly disease eligible . 4 . Patients brain metastasis may participate : • undergone appropriate treatment , least 1 month posttreatment , neurologic symptom , steroid , followup magnetic resonance imaging ( MRI ) scan demonstrate residual active lesion , new untreated lesion . 5 The following prior therapy allow : No prior chemotherapy metastatic setting . However , patient must receive prior adjuvant neoadjuvant chemotherapy . Prior radiation therapy either metastatic earlystage setting , long &lt; 25 % bone marrow treat . Radiation therapy must complete least 14 day prior study registration , radiationrelated toxicity must resolve ≤ grade 1 patient eligible study inclusion . Any number hormonal therapy neoadjuvant , adjuvant , metastatic setting allow . Patients must discontinue hormonal therapy least 1 week prior start study treatment . •Prior bevacizumab administer &gt; 4 week initiation study treatment allow . 6 HER2negative status . Documentation HER2 result must available time study enrollment . HER2negative define : Immunohistochemical ( IHC ) 0 IHC 1+ OR Fluorescence situ hybridization ( FISH ) negative ( define FISH ratio &lt; 2.2 ) OR Silver insitu hybridization ( SISH ) negative ( define SISH ratio &lt; 2.2 ) . Patients IHC 2+ need validate HER2negative FISH . 7 An Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; = 2 . 8 . Normal bone marrow function define : absolute neutrophil count ( ANC ) &gt; 1,500/μL ; platelet &gt; 100,000/μL ; hemoglobin &gt; 9 g/dL . 9 Normal hepatic function define : total bilirubin within normal institutional limit ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2.5 × institutional upper limit normal ( ULN ) patient without liver metastasis ; &lt; 5.0 × ULN patient liver metastasis . 10 . Normal renal function define creatinine &lt; 1.5 × ULN . 11 . Left ventricular ejection fraction ( LVEF ) within institutional limit normal . 12. International normalize ratio ( INR ) &lt; 1.5 prothrombin time/partial thromboplastin time ( PT/PTT ) within normal limit . Patients receive anticoagulation treatment agent warfarin heparin may allow participate . The INR measure prior initiation sorafenib , patient warfarin , INR monitor least weekly follow initiation protocol treatment , INR stable therapeutic . 13 . Life expectancy &gt; 6 month . 14 . For woman childbearing potential , negative serum pregnancy test within 7 day prior start treatment . 15 . For woman childbearing potential men , agreement use method contraception acceptable physician time first signing inform consent study duration . Men use adequate birth control least three month last administration sorafenib . If woman become pregnant suspect pregnant participate study , must agree inform treat physician immediately . As applicable , patient must agree discontinue breastfeed least 3 week last dose study drug . 16 . Recovery &lt; grade 1 toxicity due prior therapy . 17 . Ability understand willingness sign write informed consent document . Exclusion Criteria 1 . More one ( &gt; 1 ) prior chemotherapy regimen . 2 . Treatment chemotherapy , biologic agent , target agent within previous 4 week . 3 . Previous treatment sorafenib ixabepilone . 4 . Women pregnant breastfeeding . 5 . Neuropathy ( motor sensory ) great grade 1 . 6 . Uncontrolled intercurrent illness include ( limited ) ongoing active infection &gt; grade 2 . 7 . Known history human immunodeficiency virus ( HIV ) , Hepatitis B , Hepatitis C infection . 8 . History nonbreast cancer malignancy treat curative intent within 5 year precede study enrollment exception carcinoma situ cervix , nonmelanoma skin cancer , follicular thyroid cancer . 9 . Concurrent hormonal therapy , chemotherapy ixabepilone , radiation treatment study well treatment investigational agent study . 10 . Cardiac disease : •Congestive heart failure ( CHF ) great New York Heart Association ( NYHA ) Class II ( see Appendix B ) . Unstable angina ( anginal symptom rest ) new onset angina ( i.e. , begin within last 3 month ) . Myocardial infarction within past 6 month . Cardiac ventricular arrhythmia require antiarrhythmic therapy . 11 . Uncontrolled hypertension ( systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 100 mmHg despite optimal medical management ) . 12 . Thrombolic embolic event cerebrovascular accident , include transient ischemic attack , within past 6 month . 13 . Pulmonary hemorrhage bleed event ≥ grade 2 within 4 week first dose study treatment , hemorrhage bleed event ≥ grade 3 within 4 week first dose study treatment . 14 . Serious nonhealing wound , ulcer , bone fracture . 15 . Evidence history bleed diathesis coagulopathy . 16 . Major surgery , open biopsy significant traumatic injury within 4 week first dose study drug anticipation need major surgical procedure . 17 . Chronic use CYP3A4 inducer use follow strong CYP3A4 inhibitor : ketoconazole , itraconazole , clarithromycin , atazanavir , nefazodone , saquinavir , telithromycin , ritonavir , amprenavir , indinavir , nelfinavir , delavirdine , voriconazole . Use agent discontinue least 72 hour prior initiation study treatment . 18 . Use St. John 's Wort rifampin ( rifampicin ) . 19 . Any condition impair patient 's ability swallow whole pill gastrointestinal ( GI ) tract disease involve inability take oral medication , malabsorption syndrome , requirement intravenous ( IV ) alimentation , prior surgical procedure affect absorption , uncontrolled inflammatory GI disease ( e.g. , Crohn 's disease ulcerative colitis ) . 20 . Psychiatric illness/social situation would limit compliance study requirement . 21 . Known suspected allergy sorafenib , Cremophor EL ( polyoxyethylated castor oil ) drug formulate Cremophor EL paclitaxel agent give course trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Nexavar</keyword>
	<keyword>Ixabepilone</keyword>
	<keyword>Ixempra</keyword>
</DOC>